Drugs / AP611074
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01532102 | Feb 2012 → May 2013 | anogenital human papillomavirus infection | Anaconda Pharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02724254 | Jan 2016 → May 2018 | anogenital human papillomavirus infection | Vaxart | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP611074 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01532102 ↗ |
| Action | Inhibit | “potent and selective inhibitor of the interaction between two viral proteins from HPV6 and HPV11” NCT01532102 ↗ |
| Modality | Small molecule | “AP611074 is a synthetic new chemical entity” NCT01532102 ↗ |
| Route | Topical | “topical application of AP611074 5% gel” NCT01532102 ↗ |